

**Express Mail No.: EL 501 641 812 US** 

-#9/A BP 10-15-01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Karsenty et al.

Application No.: 09/489,873 Group Art Unit: 1635

Filed: January 20, 2000 Examiner: Lacourciere, K.

For: METHODS AND COMPOSITIONS

FOR CONTROL OF BONE

FORMATION VIA MODULATION

OF LEPTIN ACTIVITY

Attorney Docket No.: 9142-006-999

## PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.121

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination of the above-captioned application, please enter the following amendments and consider the following remarks. Applicants submits concurrently herewith: (a) a marked up version of the replacement paragraphs of the specification showing the amendments made, attached hereto as Exhibit A; and (b) a replacement paragraphs of the specification, attached hereto as Exhibit B.

## **IN THE SPECIFICATION:**

A marked up version of the replacement paragraphs of the specification is attached hereto as Exhibit A. Matter that has been added to the specification is indicated by underlining.

Please amend the specification as follows:

On page 67, please replace the paragraph beginning "While antisense" with the following paragraph:

While antisense nucleotides complementary to the Ob or ObR coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred. For example, antisense oligonucleotides to the ObR coding region having the following sequences can be utilized in accordance with the invention: